Personalis Retained Earnings (Accumulated Deficit) 2018-2024 | PSNL

Personalis retained earnings (accumulated deficit) from 2018 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Personalis Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $-469
2022 $-360
2021 $-247
2020 $-182
2019 $-141
2018 $-116
2017 $
Personalis Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-09-30 $-534
2024-06-30 $-494
2024-03-31 $-482
2023-12-31 $-469
2023-09-30 $-442
2023-06-30 $-413
2023-03-31 $-389
2022-12-31 $-360
2022-09-30 $-329
2022-06-30 $-303
2022-03-31 $-275
2021-12-31 $-247
2021-09-30 $-227
2021-06-30 $-209
2021-03-31 $-194
2020-12-31 $-182
2020-09-30 $-169
2020-06-30 $-159
2020-03-31 $-150
2019-12-31 $-141
2019-09-30 $-134
2019-06-30 $-127
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.239B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
Dr Reddy's Laboratories (RDY) India $11.677B 22.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00